Worldwide Prescription Drug Market for Womens Health

Content

• 1. Introduction to the Women's Health Rx Drug Market
  • 1.1 Overview
  • 1.2 The Importance of Rx Drugs for Women's Health
    • 1.2.1 Drugs Can Help Prevent Or Cure Diseases Such As Osteoporosis, HIV/AIDS, and others.
    • 1.2.2 Help their quality of life
    • 1.2.3 Women Are Usually The Caregiver And Health Care Decision-Makers In Their Family.
    • 1.2.4 Women Have Different Drug Needs Than Men.
    • 1.2.5 Osteoporosis Is Another Silent Disease In Women's Health.
    • 1.2.6 Women Have Infertility Issues
    • 1.2.7 And More
  • 1.3 Main Drug Therapy Areas
    • 1.3.1 Autoimmune Conditions
      • 1.3.1.1 Rheumatoid Arthritis
      • 1.3.1.2 Scleroderma
      • 1.3.1.3 Sjogren's Syndrome
      • 1.3.1.4 Systemic Lupus Erythematosus
      • 1.3.1.5 Multiple Sclerosis
      • 1.3.1.6 Chronic Idiopathic Thrombocytopenic Purpura
      • 1.3.1.7 Chronic Fatigue Syndrome
      • 1.3.1.8 Fibromyalgia
    • 1.3.2 Cancer
      • 1.3.2.1 Breast Cancer
      • 1.3.2.2 Cervical Cancer
      • 1.3.2.3 Ovarian Cancer
      • 1.3.2.4 Uterine Cancer (same as Endometrial)
    • 1.3.3 Gynecological Infections and STDs
      • 1.3.3.1 HIV/AIDS
      • 1.3.3.2 Bacterial Vaginosis
      • 1.3.3.3 Chlamydia
      • 1.3.3.4 Genital Herpes (HSV-1&2)
      • 1.3.3.5 HPV Infection
      • 1.3.3.6 Gonorrhea
      • 1.3.3.7 Hepatitis B and C
      • 1.3.3.8 Pelvic Inflammatory Disease
      • 1.3.3.9 Syphilis
      • 1.3.3.10 Yeast (Candida) Infections
    • 1.3.4 Menopause and Hormones
      • 1.3.4.1 Endometriosis
      • 1.3.4.2 Uterine Fibroids
      • 1.3.4.3 Menopause
      • 1.3.4.4 Amenorrhea
      • 1.3.4.5 Dysmenorrhea
    • 1.3.5 Osteoporosis
    • 1.3.6 Reproductive Related Therapies
      • 1.3.6.1 Contraception
      • 1.3.6.2 Infertility
    • 1.3.7 Female Sexual Dysfunction
    • 1.3.8 Urologic and Kidney
      • 1.3.8.1 Incontinence
      • 1.3.8.2 Interstitial Cystitis
      • 1.3.8.3 Urinary Tract Infections
• 2. Women's Health Rx Drug Market View by Disease Chapter
  • 2.2 Autoimmune Conditions
    • 2.2.1 Overview
    • 2.2.2 Autoimmune Incidence, Prevalence, Mortality & Growth by Indication
    • 2.2.3 Autoimmune Drug Treatments, Makers & Revenue by Indication
    • 2.2.4 Autoimmune New Drug Pipeline by Indication
    • 2.2.5 Important Finding (Special Note)
  • 2.3 Cancer
    • 2.3.1 Overview
    • 2.3.2 Cancer Incidence, Prevalence, Mortality & Growth by Indication
    • 2.3.3 Cancer Drug Treatments, Makers & Revenue by Indication
    • 2.3.4 Cancer New Drug R&D Pipeline/Commercial Implication by Indication
    • 2.3.5 Important Finding (Special Note)
  • 2.4 Gynecological Infections and STDs
    • 2.4.1 Overview
    • 2.4.2 Gynecological Infections Incidence, Prevalence, Mortality & Growth by Indication
    • 2.4.3 Gynecological Infections Drug Treatments, Makers & Revenue by Indication
    • 2.4.4 Gynecological Infections & STD Drug R&D Pipeline by Indication
    • 2.4.5 Important Finding (Special Note)
  • 2.5 Menopause and Hormones
    • 2.5.1 Overview
    • 2.5.2 Menopause & Hormones Incidence, Prevalence, Mortality & Growth 2003
    • 2.5.3 Menopause & Hormone Drug Treatments, Makers & Revenue by Indication
    • 2.5.4 Menopause & Hormone Drug R&D Pipeline by Indication
    • 2.5.5 Important Finding (Special Note)
  • 2.6 Osteoporosis
    • 2.6.1 Overview
    • 2.6.2 Osteoporosis Incidence, Prevalence, Mortality & Growth
    • 2.6.3 Osteoporosis Drug Treatments, Makers & Revenue by Indication
    • 2.6.4 Osteoporosis Drug R&D Pipeline & Commercial Implication Indication
    • 2.6.5 Important Finding (Special Note)
  • 2.7 Reproductive Related Therapies
    • 2.7.1 Overview
    • 2.7.2 Reproductive Incidence, Prevalence, Mortality & Growth by Indication
    • 2.7.3 Reproductive Drug Treatments, Makers & Revenue by Indication
    • 2.7.4 Reproductive Related Drug R&D Pipeline & Commercial Implication
    • 2.7.5 Important Finding (Special Note)
  • 2.8 Female Sexual Dysfunction
    • 2.8.1 Overview
    • 2.8.2 Female Sexual Dysfunction Incidence, Prevalence, Mortality & Growth by Indication
    • 2.8.3 Female Sexual Dysfunction Drug Treatments, Makers & Revenue by Indication
    • 2.8.4 Female Sexual Dysfunction Drug R&D Pipeline & Commercial Implication Indication
    • 2.8.5 Important Finding (Special Note)
  • 2.9 Urologic and Kidney
    • 2.9.1 Overview
    • 2.9.2 Urologic & Kidney Incidence, Prevalence, Mortality & Growth by Indication
    • 2.9.3 Urologic & Kidney Drug Treatments, Makers & Revenue by Indication
    • 2.9.4 Urologic & Kidney Drug R&D Pipeline & Commercial Implication Indication
    • 2.9.5 Important Finding (Special Note)
• 3. Women's Health Rx Drug Market Size Forecast by Disease
  • 3.1 Total Market Size Forecast 2004E-2009P
    • 3.2.1 Forecast for 'Autoimmune' Segment
    • 3.1.2 Forecast Methodology
  • 3.2 Market Size Forecast by Disease Segment 2004E-2009E
    • 3.2.2 Forecast for 'Cancer' Segment
    • 3.2.3 Forecast for 'Gyn. Infections & STDs' Segment
    • 3.2.4 Forecast for 'Female Sexual Dysfunction' Segment
    • 3.2.5 Forecast for 'Menopause & Hormones' Segment
    • 3.2.6 Forecast for 'Osteoporosis' Segment
    • 3.2.7 Forecast for 'Reproductive Related' Segment
    • 3.2.8 Forecast for 'Urological & Kidney' Segment
  • 3.3 WH Market Size Forecast by Disease Segment Breakdown
    • 3.3.1 Forecast for 'Autoimmune' Indications
    • 3.3.2 Forecast for 'Cancer' Indications
    • 3.3.3 Forecast for 'Female Sexual Dysfunction'
    • 3.3.4 Forecast for 'Osteoporosis'
    • 3.3.5 Forecast for 'Gynecological Infections & STD' Indications
    • 3.3.6 Forecast for the 'Menopause and Hormones' Indications
    • 3.3.7 Forecast for the 'Reproductive Related' Indications
    • 3.3.8 Forecast the 'Urologic and Kidney' Indications
    • 3.3.9 WH Rx Market Size Forecast by Disease Segment Breakdown 2004-2009 ($M)
  • 3.4 Share of Market by Disease Segments, 2005 & 2009
  • 3.5 Market Size Forecast by WW Regions
  • 3.6 Top Ranking 3-5 Drug Makers By Disease in WW WH Market
• 4. Profiles of Pharma & Biotech Companies in Women's Health
  • 4.1 Abbott Labs
  • 4.2 Akzo Nobel
  • 4.3 Allergan
  • 4.4 Amgen
  • 4.5 Astellas Pharma
  • 4.6 AstraZeneca
  • 4.7 Barr Labs
  • 4.8 Bayer Healthcare
  • 4.9 Biogen-Idec
  • 4.10 Bristol-Myers Squibb
  • 4.11 Chiron
  • 4.12 Eli Lilly
  • 4.13 Forest Laboratories
  • 4.14 Genentech
  • 4.15 Gilead Sciences
  • 4.16 GlaxoSmithKline
  • 4.17 Johnson & Johnson
  • 4.18 Kyowa Hakko
  • 4.19 Merck & Co
  • 4.20 Novartis AG
  • 4.21 Pfizer
  • 4.22 Roche Group
  • 4.23 Sanofi-Aventis
  • 4.24 Schering AG
  • 4.25 Schering-Plough
  • 4.26 Serono AG
  • 4.27 Shire Pharmaceutical
  • 4.28 Solvay Pharmaceuticals
  • 4.29 Takeda Chemical
  • 4.30 Teva Pharmaceuticals
  • 4.31 Warner Chilcott PLC
  • 4.32 Watson Pharmaceuticals
  • 4.33 Wyeth Pharmaceuticals
• 5. Appendix
  • 5.1 Women's Health Industry Web Links
• List of Tables
  • Table 1. Pct. of WW Female Population by Disease Incidence/ Prevalence
  • Table 2. Autoimmune Incidence, Prevalence, Mortality & Growth 2003E
  • Table 3. Autoimmune Incidence, Prevalence, Mortality & Growth 2004P
  • Table 4. Autoimmune Drugs, Makers & Revenue by Indication
  • Table 5. Autoimmune Drug R&D Pipeline & Commercial Implication Indication
  • Table 6. Cancer Incidence, Prevalence, Mortality & Growth 2003
  • Table 7. Cancer Incidence, Prevalence, Mortality & Growth 2004P
  • Table 8. Cancer Drugs, Makers & Revenue by Indication
  • Table 9. Cancer Drugs R&D Pipeline & Commercial Implication Indication
  • Table 10. GYN Infections Incidence, Prevalence, Mortality & Growth 2003
  • Table 11. GYN Infections Incidence, Prevalence, Mortality & Growth 2004P
  • Table 12. GYN Infection & STD Drugs, Makers & Sales by Indication
  • Table 13. GYN Infection & STD Drug R&D Pipeline by Indication
  • Table 14. Menopause & Hormones Incidence, Prevalence, Mortality & Growth 2003
  • Table 15. Menopause & Hormones Incidence, Prevalence, Mortality & Growth 2004
  • Table 16. Menopause & Hormones Drugs, Makers & Revenue by Indication
  • Table 17. Menopause & Hormone Drug R&D Pipeline by Indication
  • Table 18. Osteoporosis Incidence, Prevalence, Mortality & Growth
  • Table 19. Osteoporosis Incidence, Prevalence, Mortality & Growth by Indication 2004
  • Table 20. Osteoporosis Drugs, Makers & Revenue by Indication
  • Table 21. Osteoporosis Drug R&D Pipeline & Commercial Implication Indication
  • Table 22. Reproductive Incidence, Prevalence, Mortality & Growth by Indication
  • Table 23. Reproductive Incidence, Prevalence, Mortality & Growth 2004P
  • Table 24. Reproductive Drugs, Makers & Revenue by Indication
  • Table 25. Reproductive Related Drug R&D Pipeline & Commercial Implication
  • Table 26. Female Sexual Dysfunction Incidence, Prevalence, Mortality & Growth by Indication, 2003
  • Table 27. Female Sexual Dysfunction Incidence, Prevalence, Mortality & Growth by Indication, 2004
  • Table 28. Female Sexual Dysfunction Drugs, Makers & Revenue by Indication
  • Table 29. Female Sexual Dysfunction Drug R&D Pipeline & Commercial Implication Indication
  • Table 30. Urologic & Kidney Incidence, Prevalence, Mortality & Growth by Indication
  • Table 31. Urologic & Kidney Incidence, Prevalence, Mortality & Growth 2004
  • Table 32. Urologic & Kidney Drugs, Makers & Revenue by Indication
  • Table 33. Urologic & Kidney Drug R&D Pipeline & Commercial Implication Indication
  • Table 34. Total WH Rx Market Size Forecast 2004E-2009E ($M)
  • Table 35. WH Rx Market Size Forecast by Disease Segment 2004E-2009P ($M)
  • Table 36. Share of Market by Disease Segments, 2005 & 2009
  • Table 37. Women's Health Rx Market Size Forecast by WW Regions
  • Table 38. Top Ranking 3-5 Current & New Pipeline Drug Makers By Disease
• List of Figures
  • Figure 1. Worldwide Women's Health Rx Drug Market Map
  • Figure 2. Total Women's Health Rx Market Size Forecast 2004E-2009P
  • Figure 3. WH Rx Market Size Forecast by Disease Segment 2004E-2009P ($M)
  • Figure 4. Market Size by 'Autoimmune, Part 1' Indication Rx Revenues
  • Figure 5. Market Size by 'Autoimmune, Part 2' Indication Rx Revenues
  • Figure 6. Market Size by 'Cancer' Indication Rx Revenues
  • Figure 7. Market Size by 'Female Sexual Dysfunction' Rx Revenues
  • Figure 8. Market Size by 'Osteoporosis' Rx Revenues
  • Figure 9. Market Size by 'Gyn. Infections & STDs, Part 1' Indication Rx Revenues
  • Figure 10. Market Size by 'Gyn. Infections & STDs, Part 2' Indication Rx Revenues
  • Figure 11. Market Size by 'Menopause and Hormones' Indication Rx Revenues
  • Figure 12. Market Size by 'Reproductive Related' Indications Rx Revenues
  • Figure 13. Market Size by 'Urologic and Kidney' Indications Rx Revenues
  • Figure 14. Share of Market by Disease Segments, 2005 & 2009
  • Figure 15. Women's Health Rx Market Size Forecast by WW Regions To 2009